Bristol-Myers Squibb Company (BMY)

67.34
NYSE
Prev Close 67.39
Day Low/High 66.78 / 67.94
52 Wk Low/High 54.07 / 67.96
Exchange NYSE
Shares Outstanding 2233.93B
Market Cap 150.54B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

2 Biotech Stocks That Appear Undervalued Based on Their Prospects

2 Biotech Stocks That Appear Undervalued Based on Their Prospects

Agenus Inc. and uniQure N.V. recently have announced positive news developments that should boost their long-term prospects.

Jim Cramer: Here's What Can Go Higher

Jim Cramer: Here's What Can Go Higher

Let's look at the companies that can go up, and the ones that can't.

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

Economics for Dummies, Fed Recap, Fun With Jobs Math, Amazon, Buying ServiceNow

The differences in approach between the two most basic strategies for how to grow an economy are as stark as the division they cause among economists.

A Blue Chip Healthcare Stock for Growth And Yield

A Blue Chip Healthcare Stock for Growth And Yield

Bristol-Myers offers a terrific combination of yield, dividend safety, and dividend growth for income-focused investors.

Is Bristol-Myers Squibb Finally Ready for a Breakout?

Is Bristol-Myers Squibb Finally Ready for a Breakout?

Prices have rallied from early March and are in a position to test their January highs.

Looking at Bristol-Myers Again as the Quants Downgrade It

Looking at Bristol-Myers Again as the Quants Downgrade It

At current levels BMY is sort-of in no man's land - not bullish and not bearish.

Here Are 2 Biotechs That Posted Strong Earnings

Here Are 2 Biotechs That Posted Strong Earnings

Exelixis and Ultragenyx Pharmaceutical are cash rich mid-caps that don't look overbought.

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

Turn of the Worm, Treasury Curve, Manchin's Might, Trading Microsoft, Spotify

There is a point where if longer-dated yields move high enough, defensive-minded investors will be drawn from equities to debt securities.

Jim Cramer: Looking for Gold? Go With Science

Jim Cramer: Looking for Gold? Go With Science

A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.

Bristol-Myers Squibb Could Finally Make Its Move

Bristol-Myers Squibb Could Finally Make Its Move

Traders should stay long and consider increasing their exposure.

How to Play Emergent BioSolutions Right Now

How to Play Emergent BioSolutions Right Now

A correction in EBS could soon set up an attractive opportunity.

The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events

The Week That Was, Q4 Earnings Expectations, Key Investor and Healthcare Events

This Friday several banks begin the unofficial kickoff of 'earnings season'.

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

How I'm Playing Astra-Zeneca on Vaccine and Acquisition News

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.

This Trio of Diverse Stocks Makes for Interesting Stalking

This Trio of Diverse Stocks Makes for Interesting Stalking

The technical patterns of Boeing, Bristol-Myers Squibb and DraftKings are worth tracking for potential buys.

Eli Lilly: Back From the Depths

Eli Lilly: Back From the Depths

I am flat LLY for now. Let's see how the shares behave around the technicals. Then we'll make an equity decision.

Election Hindsight, Treasury Yields, Fed Day, Chip Stock Setup, A Great Trade

Election Hindsight, Treasury Yields, Fed Day, Chip Stock Setup, A Great Trade

The most important market takeaway right now is that both the Nasdaq Composite and S&P 500 have filled their respective gaps and retaken their 50-day simple moving averages.

Jim Cramer: Let's Bust These Election Myths

Jim Cramer: Let's Bust These Election Myths

These are the top five misconceptions about presidential elections -- and the stocks that you should look at right now.

Jim Cramer: Here's Why the President Is Gambling With Stimulus

Jim Cramer: Here's Why the President Is Gambling With Stimulus

The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.

Bristol-Myers Squibb Could Soon Break Out of a Large Triangle Pattern

Bristol-Myers Squibb Could Soon Break Out of a Large Triangle Pattern

Aggressive traders could go long BMY at two price levels.

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.

Jim Cramer: Does Everyone Out There Perceive That Everything Is a Win?

Jim Cramer: Does Everyone Out There Perceive That Everything Is a Win?

It's remarkable to see such excitement based on totally contradictory theories and themes.

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.

Jim Cramer: Diversification Is the Key to Getting Through This Market Upheaval

Jim Cramer: Diversification Is the Key to Getting Through This Market Upheaval

This diversification strategy lets you to capture stock market upside, while not risking your shirt.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.